RxDoctor Payments Data

Jaspreet Dhanjal, DO

Internal Medicine · Roseville, CANPI 1003378118

Payments from drug & device makers

$1,517in general payments, 2019–2025

Across 69 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$508
  • AstraZeneca$400
  • Exact Sciences$136
  • Edwards Lifesciences$89
  • Corcept Therapeutics$75
  • Lilly USA, LLC$53
  • plus $256 from 9 others

What the payments were for

  • Food & beverage$1,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,517 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$56,670
Medicare patients
158
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$43,766
OzempicSemaglutide44$41,143
JardianceEmpagliflozin24$29,830
FarxigaDapagliflozin Propanediol24$17,574
XareltoRivaroxaban20$16,496
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,123
Breo ElliptaFluticasone/Vilanterol21$7,758
Atorvastatin Calcium188$2,754
Levothyroxine Sodium149$1,936
Albuterol Sulfate HfaAlbuterol Sulfate55$1,333
Gabapentin81$1,258
Amlodipine Besylate157$947
Tamsulosin Hcl53$915
Lisinopril86$730
Losartan Potassium89$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$43,76657 claims
Novo NordiskOzempic$508$41,14344 claims
GSKTrelegy Ellipta, Breo Ellipta$44$19,88138 claims
AstraZenecaFarxiga$400$17,57424 claims
Johnson & JohnsonXarelto$14$16,49620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →